129 related articles for article (PubMed ID: 33423777)
21. Toxicities, dose reduction and delay of docetaxel and paclitaxel chemotherapy in breast cancer without distant metastases.
Kim WY; Woo SU; Seo JH; Son GS; Lee JB; Bae JW
J Cancer Res Ther; 2011; 7(4):412-5. PubMed ID: 22269401
[TBL] [Abstract][Full Text] [Related]
22. A phase II study of docetaxel weekly in combination with carboplatin every three weeks as first line chemotherapy in stage IIB-IV epithelial ovarian cancer: neurological toxicity and quality-of-life evaluation.
Sorbe B; Graflund M; Nygren L; Horvath G; Swahn M; Boman K; Bangshöj R; Lood M; Malmström H
Int J Oncol; 2012 Mar; 40(3):773-81. PubMed ID: 22159569
[TBL] [Abstract][Full Text] [Related]
23. Nail toxicity related to taxanes.
Mourad YA; Matta-Muallem M; Shamseddine A
Dermatol Online J; 2003 Aug; 9(3):15. PubMed ID: 12952762
[TBL] [Abstract][Full Text] [Related]
24. Influence of smoking on the pharmacokinetics and toxicity profiles of taxane therapy.
de Graan AJ; Loos WJ; Friberg LE; Baker SD; van der Bol JM; van Doorn L; Wiemer EA; van der Holt B; Verweij J; Mathijssen RH
Clin Cancer Res; 2012 Aug; 18(16):4425-32. PubMed ID: 22645049
[TBL] [Abstract][Full Text] [Related]
25. [Support of hematological homeostasis during chemotherapy with taxanes].
Koroleva IA; Mochalova AS
Vopr Onkol; 2011; 57(6):784-8. PubMed ID: 22416398
[TBL] [Abstract][Full Text] [Related]
26. Clinical features of taxane neuropathy.
Kudlowitz D; Muggia F
Anticancer Drugs; 2014 May; 25(5):495-501. PubMed ID: 24300917
[TBL] [Abstract][Full Text] [Related]
27. Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer.
Puglisi F; Cardellino GG; Crivellari D; Di Loreto C; Magri MD; Minisini AM; Mansutti M; Andreetta C; Russo S; Lombardi D; Perin T; Damante G; Veronesi A
Ann Oncol; 2008 Sep; 19(9):1541-6. PubMed ID: 18441329
[TBL] [Abstract][Full Text] [Related]
28. Low-dose docetaxel/cisplatin - leucovorin and 46 hour infusional fluorouracil in metastatic gastric carcinoma.
Alici S; Buyukberber S; Alkis N; Benekli M; Ozkan M; Bilici A; Demirci U; Karaca H; Arpaci E; Gumus M; Altunbas M; Dane F; Turk HM;
Asian Pac J Cancer Prev; 2013; 14(1):423-7. PubMed ID: 23534766
[TBL] [Abstract][Full Text] [Related]
29. Genetic polymorphisms and paclitaxel- or docetaxel-induced toxicities: A systematic review.
Frederiks CN; Lam SW; Guchelaar HJ; Boven E
Cancer Treat Rev; 2015 Dec; 41(10):935-50. PubMed ID: 26585358
[TBL] [Abstract][Full Text] [Related]
30. Management of toxicities associated with the administration of taxanes.
Markman M
Expert Opin Drug Saf; 2003 Mar; 2(2):141-6. PubMed ID: 12904114
[TBL] [Abstract][Full Text] [Related]
31. Irreversible and severe alopecia following docetaxel or paclitaxel cytotoxic therapy for breast cancer.
Prevezas C; Matard B; Pinquier L; Reygagne P
Br J Dermatol; 2009 Apr; 160(4):883-5. PubMed ID: 19222453
[No Abstract] [Full Text] [Related]
32. Chemotherapy-induced peripheral neuropathy among patients with ovarian cancer.
Jin L; Zhang Y; Yang W
Int J Gynaecol Obstet; 2020 Jun; 149(3):303-308. PubMed ID: 32133643
[TBL] [Abstract][Full Text] [Related]
33. Outpatient platinum-taxane intraperitoneal chemotherapy regimen for ovarian cancer.
Seamon LG; Carlson MJ; Richardson DL; Cohn DE; Fowler JM; Copeland LJ; O'Malley DM
Int J Gynecol Cancer; 2009 Oct; 19(7):1195-8. PubMed ID: 19823054
[TBL] [Abstract][Full Text] [Related]
34. Nail changes during docetaxel containing combination chemotherapy.
Woo IS; Shim KH; Kim GY; Lee MA; Kang JH; Hong YS; Lee KS
Korean J Intern Med; 2004 Jun; 19(2):132-3. PubMed ID: 15366647
[TBL] [Abstract][Full Text] [Related]
35. 5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial.
Roth AD; Maibach R; Fazio N; Sessa C; Stupp R; Morant R; Herrmann R; Borner MM; Goldhirsch A; de Braud F
Ann Oncol; 2004 May; 15(5):759-64. PubMed ID: 15111343
[TBL] [Abstract][Full Text] [Related]
36. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
[TBL] [Abstract][Full Text] [Related]
37. Docetaxel-induced onycholysis: the role of subungual hemorrhage and suppuration.
Roh MR; Cho JY; Lew W
Yonsei Med J; 2007 Feb; 48(1):124-6. PubMed ID: 17326255
[TBL] [Abstract][Full Text] [Related]
38. Interaction between Herceptin and taxanes.
Diéras V; Beuzeboc P; Laurence V; Pierga JY; Pouillart P
Oncology; 2001; 61 Suppl 2():43-9. PubMed ID: 11694787
[TBL] [Abstract][Full Text] [Related]
39. Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO).
Roth AD; Maibach R; Martinelli G; Fazio N; Aapro MS; Pagani O; Morant R; Borner MM; Herrmann R; Honegger H; Cavalli F; Alberto P; Castiglione M; Goldhirsch A
Ann Oncol; 2000 Mar; 11(3):301-6. PubMed ID: 10811496
[TBL] [Abstract][Full Text] [Related]
40. A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group.
ten Bokkel Huinink WW; Prove AM; Piccart M; Steward W; Tursz T; Wanders J; Franklin H; Clavel M; Verweij J; Alakl M
Ann Oncol; 1994 Jul; 5(6):527-32. PubMed ID: 7918124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
